A Proof of Concept Trial of a Sirtuin-NAD Activator in Alzheimer's Disease
Latest Information Update: 12 May 2023
At a glance
- Drugs MIB-626 (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Biomarker; Pharmacokinetics; Proof of concept
- 09 May 2023 Planned primary completion date changed from 29 Feb 2024 to 30 Apr 2024.
- 29 Jun 2022 Status changed from not yet recruiting to recruiting.
- 20 Sep 2021 Planned primary completion date changed from 30 Jun 2024 to 29 Feb 2024.